Polymyalgia rheumatica

1. High-Yield Summary

Polymyalgia rheumatica (PMR) is the most common chronic systemic inflammatory rheumatic disorder affecting older adults, occurring exclusively in individuals aged 50 years and older with peak incidence in the eighth decade of life. It is clinically characterized by the sudden or subacute onset of bilateral, symmetric shoulder girdle, pelvic girdle, and neck aching accompanied by profound, debilitating morning stiffness lasting greater than 45 to 60 minutes.

• The Diagnostic Hallmark and 72-Hour Steroid Response: PMR is diagnosed primarily on clinical grounds supported by markedly elevated systemic inflammatory markers (erythrocyte sedimentation rate [ESR] and C-reactive protein [CRP]) alongside strictly normal muscle enzymes (creatine kinase and aldolase). A rapid, dramatic clinical response (> 70% to 80% resolution of pain and stiffness) within 48 to 72 hours of initiating low-dose systemic corticosteroids (prednisone 12.5 to 25 mg/day) represents an indispensable diagnostic confirmation.
• Periarticular Bursal and Tenosynovial Target Architecture: Unlike rheumatoid arthritis, PMR does not produce erosive joint destruction or invasive pannus. Its cardinal anatomical phenotype consists of bilateral subacromial-subdeltoid (SASD) bursitis, long head of the biceps brachii tenosynovitis, and hip trochanteric bursitis with mild glenohumeral and coxofemoral synovitis, readily verified on point-of-care musculoskeletal ultrasound.
• Mandatory Giant Cell Arteritis (GCA) Surveillance: PMR exists on a disease continuum with Giant Cell Arteritis; 15% to 20% of patients with PMR harbor concomitant GCA, and 40% to 60% of patients with GCA manifest PMR features. Clinicians must systematically query and examine for cranial signs (new temporal headache, scalp tenderness, jaw claudication, visual blur, amaurosis fugax), which mandate immediate high-dose glucocorticoid therapy (prednisone 40 to 60 mg/day) and temporal artery biopsy to prevent permanent anterior ischemic optic neuropathy.
• Protracted Taper and High Relapse Frequency: PMR follows a prolonged course typically requiring 12 to 24 months of gradual glucocorticoid tapering. Clinical relapse occurs in approximately 50% of patients, predominantly when the daily prednisone dose is tapered below 10 mg/day. Adjunctive steroid-sparing therapy with oral methotrexate or targeted interleukin-6 (IL-6) receptor antagonists (sarilumab) is indicated in refractory disease, frequent relapses, or high glucocorticoid risk.
• Orthopaedic Misadventure Avoidance: Bilateral shoulder aching and functional impairment frequently lead to misdiagnosis as bilateral degenerative rotator cuff pathology or adhesive capsulitis in elderly patients. Recognizing preserved passive range of motion despite marked active movement restriction prevents unnecessary, non-beneficial subacromial decompression or cuff repair.

2. Anatomy

Understanding the anatomical pathology of polymyalgia rheumatica requires detailing the periarticular synovial bursae and tendon sheaths of the proximal limb girdles, as well as the vascular danger zones relevant to concomitant giant cell arteritis and surgical biopsy.

Periarticular Bursal and Tenosynovial Architecture

The musculoskeletal manifestations of PMR localize predilectively to synovial bursae, tenosynovial sheaths, and proximal articular capsules rather than the joint cartilage or subchondral bone:

• Subacromial-Subdeltoid (SASD) Bursa: One of the largest synovial bursae in the human body, the SASD bursa extends beneath the acromion, coracoacromial ligament, and deltoid muscle, resting directly upon the supraspinatus and infraspinatus tendons and the greater tuberosity of the humerus. In PMR, severe inflammatory effusion and synovial hypertrophy within the SASD bursa account for the intense anterolateral shoulder pain, marked nocturnal discomfort when recumbent, and painful arc during abduction. Bilateral SASD bursitis is the single most sensitive sonographic hallmark of the disease.
• Long Head of the Biceps Brachii Tendon (LHBT) Sheath: The synovial sheath surrounding the LHBT within the bicipital groove communicates directly with the glenohumeral joint cavity. Tenosynovial effusion and sheath hypertrophy occur in up to 70% of PMR shoulders, eliciting focal tenderness along the anterior proximal humerus that frequently mimics primary bicipital tendinitis.
• Glenohumeral Joint: Non-erosive synovitis with low-volume intra-articular effusion is observed in the majority of patients. However, the synovial proliferation remains non-destructive, with complete preservation of the glenoid and humeral head articular cartilage and absence of marginal bone erosions.
• Pelvic Girdle Bursae: The greater trochanteric bursa (situated between the gluteus medius and minimus insertions and the iliotibial band/fascia lata), the iliopectineal/iliopsoas bursa (positioned anterior to the hip capsule beneath the iliopsoas tendon), and the ischiogluteal bursa (overlying the ischial tuberosity) frequently exhibit synchronous inflammation. Greater trochanteric bursitis produces prominent lateral hip tenderness and difficulty rising from a seated position, while iliopectineal bursitis elicits deep groin ache exacerbated by passive hip extension.
• Axial Interspinous Bursae: Synovial bursae interposed between the spinous processes of the cervical and lumbar vertebrae undergo active inflammation in PMR. Interspinous bursitis accounts for severe cervical stiffness, paraspinal aching, and axial immobility that can mimic degenerative cervical spondylosis or lumbar spinal stenosis.

Vascular Danger Zones: Superficial Temporal and Ophthalmic Arteries

Due to the critical overlap between PMR and giant cell arteritis, the vascular anatomy of the cranial and ocular arterial trees represents an essential clinical and surgical consideration:

• Superficial Temporal Artery (STA): The STA arises as a terminal branch of the external carotid artery within the parotid gland, ascending across the zygomatic arch immediately anterior to the tragus within the temporoparietal fascia (superficial musculoaponeurotic system layer). It bifurcates superiorly into the frontal (anterior) and parietal (posterior) branches. Granulomatous panarteritis of the STA produces palpable induration, tenderness, erythema, and absent pulsation.
• Temporal Artery Biopsy Danger Zone: When obtaining a diagnostic surgical biopsy of the STA, the frontal branch of the facial nerve (cranial nerve VII) represents the primary motor structure at risk. The nerve courses across the zygomatic arch approximately 1.5 to 2 cm anterior to the external auditory canal within the sub-aponeurotic plane. To prevent iatrogenic frontal branch transection and permanent unilateral paralysis of the frontalis muscle (inability to elevate the eyebrow), the biopsy incision must be placed within the hairline or directed along the main trunk or parietal branch posterior to the temporal hairline.
• Ophthalmic Artery and Short Posterior Ciliary Arteries: Arising from the internal carotid artery, the ophthalmic artery gives origin to the medial and lateral short posterior ciliary arteries that supply the optic nerve head and lamina cribrosa. Granulomatous inflammatory occlusion of these end-arteries leads to anterior ischemic optic neuropathy (AION), presenting as sudden, painless, permanent visual field loss or complete monocular blindness.
• Large-Vessel Vasculature: Extracranial involvement of the aorta, subclavian, and axillary arteries occurs in a subset of patients, leading to vascular bruits, upper limb claudication, asymmetric pulses, and long-term risk of thoracic aortic aneurysm.

3. Pathogenesis

The pathogenesis of polymyalgia rheumatica involves a sophisticated interplay of immunosenescence, genetic susceptibility, innate immune hyperactivation, and a potent systemic interleukin-6 (IL-6) cytokine cascade, resulting in intense periarticular synovial inflammation without cartilage destruction.

Innate Immune Activation and Dendritic Cell Priming

The strict age restriction of PMR (exclusively in individuals aged 50 and older) strongly implicates aging of the immune system (immunosenescence) in disease susceptibility. The initiating pathological event involves the abnormal activation of adventitial and tissue-resident dendritic cells located within synovial bursae and surrounding connective tissues. Toll-like receptors (specifically TLR4 and TLR5) on these dendritic cells become primed in response to endogenous danger-associated molecular patterns (DAMPs) or unrecognized infectious triggers. Activated dendritic cells produce chemokine ligands (CCL19 and CCL21), recruiting antigen-inexperienced CD4+ T helper cells and circulating monocytes into the periarticular microenvironment.

T-Cell Polarization and the Interleukin-6 Cytokine Cascade

Recruited CD4+ T lymphocytes differentiate into distinct effector lineages, predominantly T helper 1 (Th1) cells producing interferon-gamma (IFN-gamma) and T helper 17 (Th17) cells producing interleukin-17 (IL-17) and interleukin-21. These activated T cells interact with CD14+ monocytes and macrophages within the bursal synovium, triggering massive, dysregulated secretion of pro-inflammatory cytokines, foremost among them Interleukin-6 (IL-6), alongside interleukin-1beta (IL-1beta) and tumor necrosis factor-alpha (TNF-alpha).

IL-6 serves as the primary master driver of the clinical and systemic phenotype in PMR. Circulating IL-6 enters the portal and systemic circulation, binding to hepatocytes via transmembrane and soluble IL-6 receptors to trigger the Janus kinase/signal transducer and activator of transcription (JAK/STAT) signaling pathway. This upregulates the transcription of acute-phase proteins, producing dramatic elevations in C-reactive protein (CRP), serum amyloid A, and fibrinogen (which accelerates erythrocyte rouleaux formation and drives high ESR). Centrally, IL-6 acts on the hypothalamus to produce profound fatigue, malaise, anorexia, sleep disturbance, and low-grade pyrexia. Circulating IL-6 titers correlate directly with clinical disease activity and relapse.

Absence of Cartilage Degradation and Erosive Destruction

A critical immunopathological distinction exists between polymyalgia rheumatica and rheumatoid arthritis. In PMR, bursal and synovial histological biopsies reveal intense capillary proliferation, prominent edema, and dense infiltration by CD4+ T lymphocytes and CD68+ macrophages. However, this inflammatory process remains strictly non-destructive. PMR synovium lacks the hyperplastic, invasive pannus characteristic of rheumatoid arthritis; osteoclast differentiation is not activated at the bone-synovial junction, and matrix metalloproteinase-driven chondrocyte apoptosis is absent. Consequently, the articular cartilage, subchondral bone plate, and tendon substance remain structurally intact, with complete absence of cortical erosions or joint space loss.

Immunogenetics and Epigenetics

Susceptibility to PMR is linked to major histocompatibility complex (MHC) Class II alleles, most notably HLA-DRB1*0401 and HLA-DRB1*0404. These alleles share a conserved amino acid sequence within the antigen-binding groove (the shared epitope), suggesting that presentation of specific, as-yet-unidentified autoantigens or microbial peptides plays a central role in driving clonal T-cell expansion. Polymorphisms in cytokine genes, including the IL-6 promoter region, further modulate individual susceptibility and disease severity.

4. Natural History

Polymyalgia rheumatica is a self-limiting inflammatory disorder of older adults, but its clinical trajectory without timely therapy is characterized by severe immobility, functional dependence, and substantial risk of vascular complications.

Epidemiological Profile

PMR is the second most common inflammatory rheumatologic disorder in older adults, surpassed only by rheumatoid arthritis. Key demographic characteristics include:

• Age Distribution: PMR never occurs in patients younger than 50 years. The average age of disease onset is 73 years, with peak incidence concentrated between 70 and 80 years of age.
• Sex Predilection: Women are affected approximately two to three times more frequently than men across all studied cohorts.
• Geographic and Ancestral Variation: The highest incidence worldwide is observed in populations of Northern European and Scandinavian heritage, reaching 50 to 112 per 100,000 persons aged 50 years and older annually. In contrast, incidence is markedly lower among individuals of Mediterranean, Asian, Hispanic, and African descent (less than 10 to 15 per 100,000 person-years).

Disease Progression and Untreated Course

In the absence of anti-inflammatory treatment, PMR runs an agonizing course marked by relentless morning stiffness, nocturnal aching, and severe physical incapacitation. Patients frequently become bedbound or wheelchair-dependent due to the inability to bear weight on the pelvic girdle or push up from a chair. Secondary consequences of chronic untreated disease include rapid muscle deconditioning, disuse sarcopenia, joint contractures from antalgic immobility, malnutrition, and severe clinical depression.

The disease process is inherently self-limiting, typically resolving over a timeframe of 1 to 3 years. However, spontaneous complete remission without pharmacotherapy is rare, and leaving active systemic inflammation unchecked exposes the patient to an elevated risk of developing secondary giant cell arteritis with ischemic complications.

Treated Prognosis and Relapse Dynamics

With appropriate glucocorticoid management, symptomatic recovery is rapid and dramatic. However, long-term disease management is complicated by high rates of clinical relapse. Approximately 40% to 50% of patients experience at least one disease flare during the course of corticosteroid tapering, most commonly when doses drop below 10 mg/day or during the first year of treatment. Consequently, the median duration of corticosteroid therapy required to achieve permanent remission ranges from 18 to 24 months, with approximately 25% of patients requiring low-dose maintenance therapy beyond 3 to 4 years.

Overall life expectancy in uncomplicated PMR is comparable to that of age-matched controls in the general population. However, significant secondary morbidity arises from cumulative corticosteroid toxicity, including osteoporotic fragility fractures, diabetes mellitus, cardiovascular disease, and opportunistic infections.

5. Clinical Presentation

The diagnosis of polymyalgia rheumatica relies upon a structured clinical evaluation designed to elicit characteristic symptom patterns, verify physical examination benchmarks, and exclude mimickers and concurrent giant cell arteritis.

History

Patients typically present with an abrupt or subacute onset of bilateral, symmetric aching and stiffness in the proximal limb girdles. Key historical features include:

• Temporal Pattern of Onset: Symptoms commonly develop over several days or a few weeks; many patients can identify the exact calendar day or morning their symptoms began. An onset spanning greater than several months should prompt consideration of alternative diagnoses.
• Anatomical Distribution of Pain: Bilateral shoulder girdle aching is present in nearly 100% of cases, followed by pelvic girdle involvement (hips, buttocks, anterior thighs) in 70% to 80% and neck/cervical spine pain in 50% to 70%. Pain is deep, diffuse, and poorly localized, frequently radiating down the upper arms to the elbows and down the thighs to the knees. Distal extremity pain below the elbows and knees is uncommon.
• Profound Morning Stiffness: Morning stiffness lasting greater than 45 to 60 minutes (and frequently several hours) is an indispensable clinical criterion. Patients experience pronounced “gel phenomenon,” where even short periods of daytime sitting or rest induce severe stiffness.
• Severe Functional Impairment: Patients report marked difficulty performing basic activities of daily living: rolling over in bed, sitting up from a supine position, standing from a low toilet or deep armchair without pushing with the arms, putting on an overcoat or jacket, combing hair, and fastening brassieres.
• Constitutional Symptoms: Present in one-third to one-half of patients, including profound fatigue, loss of energy, low-grade fever (temperature 38.5°C) are atypical for isolated PMR and demand urgent investigation for GCA, occult infection, or malignancy.
• Peripheral Manifestations: Approximately 20% to 30% of patients exhibit peripheral musculoskeletal involvement: mild, transient, asymmetric non-erosive oligoarthritis (knees, wrists), carpal tunnel syndrome, or distal tenosynovitis with pitting edema of the dorsum of the hands and feet (RS3PE syndrome overlap).

Physical Examination

The physical examination in PMR demonstrates marked active mobility limitations despite normal intrinsic muscular and neurological function, combined with specific palpatory findings:

• Active versus Passive Range of Motion Discrepancy: Active elevation and abduction of the shoulders are severely restricted by pain and stiffness, often halting below 90 degrees. However, when the examiner supports the limb and gently maneuvers the shoulder through passive forward flexion, abduction, and external rotation, passive range of motion is remarkably preserved or nearly normal. This classic discrepancy is the cornerstone that differentiates PMR from adhesive capsulitis (frozen shoulder) and advanced glenohumeral osteoarthritis, where passive motion is mechanically blocked in all planes.
• Integrity of Motor Strength: True motor weakness is absent. When manual muscle testing (MMT) is performed within a pain-free arc or after adequate analgesia, muscle power is 5/5. Apparent “weakness” during initial testing is attributable entirely to pain inhibition (give-way weakness). Muscle atrophy is absent in acute disease, and sensory examination and deep tendon reflexes are normal.
• Palpatory Tenderness: Gentle palpation reveals tenderness over the subacromial space, anterior bicipital groove, greater trochanters, and cervical/lumbar spinous processes. Joint swelling, erythema, and warmth are absent over the shoulders and hips.
• Systematic Giant Cell Arteritis Screening: Every patient must undergo targeted cranial and vascular assessment:
  • Palpation of the superficial temporal arteries along their course for tenderness, thickening, nodularity, beading, or diminished/absent arterial pulsations.
  • Scalp examination for localized allodynia when touching hair or skin.
  • Visual acuity, confrontation visual field testing, and fundoscopic examination to detect optic disc edema or pallor indicative of anterior ischemic optic neuropathy.
  • Auscultation of the carotid, subclavian, and femoral vessels for vascular bruits, and bilateral upper extremity blood pressure measurement to screen for large-vessel stenoses.

6. Imaging and Diagnostic Studies

The diagnostic investigation of suspected PMR follows a structured hierarchy encompassing serological laboratory benchmarks, baseline plain radiography, and point-of-care musculoskeletal ultrasound, with selective use of advanced cross-sectional imaging.

Laboratory Evaluation

Laboratory testing serves to corroborate systemic inflammation and systematically exclude primary myogenic, rheumatologic, or hematologic mimics:

• Acute Phase Reactants: Marked elevation in erythrocyte sedimentation rate (ESR > 40 to 50 mm/hr by the Westergren method, frequently exceeding 80 to 100 mm/hr) and C-reactive protein (CRP > 10 mg/L) is typical. CRP exhibits higher sensitivity (95% to 100%) than ESR (85% to 90%) and possesses faster normalization kinetics following therapy. Approximately 10% to 15% of clinically confirmed PMR cases present with a normal ESR, but virtually all exhibit an elevated high-sensitivity CRP.
• Muscle Enzymes (Strictly Normal): Serum creatine kinase (CK), aldolase, and transaminases (AST, ALT) are strictly normal. Normal muscle enzyme levels are mandatory to exclude polymyositis, dermatomyositis, immune-mediated necrotizing myopathy, statin-induced rhabdomyolysis, and metabolic myopathies.
• Autoantibody Serology (Strictly Negative): Rheumatoid factor (RF) and anti-cyclic citrullinated peptide (anti-CCP) antibodies are negative. Low-titer ANA (< 1:80) may be present as a non-specific finding of immunosenescence, but high-titer ANA, anti-dsDNA, and extractable nuclear antigens (anti-Ro/SSA, anti-La/SSB) are absent. Positive RF or anti-CCP strongly indicates late-onset rheumatoid arthritis (LORA) presenting with a polymyalgic onset.
• Complete Blood Count and Metabolic Profile: Normocytic, normochromic anemia of chronic disease (hemoglobin 10 to 12 g/dL) and reactive thrombocytosis (platelets > 400,000/uL) reflect systemic IL-6 stimulation. Serum alkaline phosphatase (ALP) is mildly elevated in 25% to 30% of patients due to hepatic cytokine release. Serum protein electrophoresis (SPEP) and serum free light chains are essential to exclude multiple myeloma or monoclonal gammopathy of undetermined significance (MGUS).

Plain Radiography

Plain radiographs of the bilateral shoulders (AP, axillary lateral, scapular Y views), pelvis (AP view), and cervical spine are characteristically normal or demonstrate age-appropriate degenerative changes. Their primary role is exclusionary:

• Ruling out advanced glenohumeral osteoarthritis (marked joint space narrowing, subchondral sclerosis, inferior humeral osteophytes).
• Excluding rotator cuff tear arthropathy (superior humeral head migration, acromial acetabularization).
• Evaluating for chondrocalcinosis (calcium pyrophosphate dihydrate deposition disease [CPPD]) in the glenohumeral joint, symphysis pubis, or hip articular cartilage.
• Excluding avascular necrosis (AVN) of the humeral or femoral head and osteolytic or osteoblastic metastatic bone lesions.

Musculoskeletal Ultrasound (MSUS)

Musculoskeletal ultrasound has emerged as the definitive point-of-care imaging modality for PMR, incorporated directly into the 2012 EULAR/ACR classification criteria. The classic sonographic triad comprises:

• Bilateral Subacromial-Subdeltoid (SASD) Bursitis: Anechoic or hypoechoic fluid distension (>= 2 mm) with thickened synovial lining within the SASD bursa. The presence of bilateral SASD bursitis possesses a sensitivity of 80% and specificity of 89% for PMR in older adults with girdle pain.
• Long Head of Biceps Tenosynovitis: Concentric fluid halo (>= 1.5 mm) surrounding the biceps tendon within the bicipital groove, demonstrating active tenosynovial inflammation.
• Coxofemoral and Trochanteric Findings: Hip joint effusion/synovitis characterized by an anterior capsular recess distension > 7 mm or asymmetry > 1 mm between sides, accompanied by fluid within the greater trochanteric bursa.
• Power Doppler Ultrasound: Typically demonstrates low-to-moderate synovial vascularity within the SASD bursa and biceps sheath, lacking the high-grade, invasive hypervascularity seen in active rheumatoid pannus.

Advanced Cross-Sectional Imaging: MRI and FDG-PET/CT

Magnetic resonance imaging (MRI) is rarely necessary in straightforward presentations but corroborates the ultrasound findings with high anatomical fidelity: extensive high-signal fluid within the SASD bursae, biceps tenosynovium, trochanteric and iliopectineal bursae, and prominent cervical/lumbar interspinous bursitis on T2-weighted and STIR sequences, without underlying bone marrow edema, cortical erosions, or rotator cuff disruption.

18F-Fluorodeoxyglucose Positron Emission Tomography / Computed Tomography (FDG-PET/CT) is valuable in atypical presentations, unexplained fever, or corticosteroid resistance. PMR manifests a pathognomonic uptake pattern: intense, symmetric FDG uptake in the shoulders, hips, ischial tuberosities, and cervical/lumbar interspinous bursae. Importantly, FDG-PET/CT detects subclinical large-vessel vasculitis (hypermetabolism of the thoracic aorta, subclavian, axillary, and carotid walls) in up to 15% to 30% of patients diagnosed with isolated PMR.

7. Classification

The diagnosis and formal clinical trial classification of polymyalgia rheumatica are governed by validated criteria systems, primarily the 2012 European League Against Rheumatism (EULAR) / American College of Rheumatology (ACR) Collaborative Initiative Classification Criteria, contextualized against historical clinical systems.

2012 EULAR/ACR Classification Criteria

The 2012 EULAR/ACR criteria were prospectively developed and validated across 1,257 patients in 10 countries to distinguish PMR from other conditions mimicking shoulder and pelvic girdle pain. Application of the criteria requires three mandatory obligatory entry criteria, followed by a scoring algorithm available in clinical-only and ultrasound-augmented formats:

• Obligatory Entry Criteria (All Must Be Met):
  • Age 50 years or older.
  • Bilateral shoulder aching.
  • Abnormal acute-phase reactants (elevated C-reactive protein and/or erythrocyte sedimentation rate).

8. Treatment

The therapeutic strategy for polymyalgia rheumatica requires prompt initiation of low-dose systemic glucocorticoids, a structured tapering protocol to maintain clinical remission while minimizing steroid toxicity, prophylactic skeletal protection, and the selective use of biologic or conventional steroid-sparing agents.

Medical / Nonoperative

Systemic pharmacotherapy is the absolute foundation of management; nonoperative modalities are detailed below:

• First-Line Glucocorticoid Induction:
  • Oral prednisone (or prednisolone) is initiated at a dose of 12.5 to 25 mg once daily in the morning. An initial dose of 15 mg/day is recommended for the vast majority of patients with standard disease severity. Higher initial doses (> 25 to 30 mg/day) are strongly discouraged for isolated PMR because they significantly increase cumulative glucocorticoid morbidity without improving long-term remission rates. Doses lower than 10 to 12.5 mg/day carry unacceptably high initial failure rates.
  • The 48 to 72-Hour Response Benchmark: Patients with PMR exhibit a dramatic, life-altering response, with > 70% to 80% improvement in pain and stiffness within 48 to 72 hours, accompanied by normalization of ESR and CRP within 2 to 4 weeks. If a patient fails to show substantial subjective and objective improvement within 5 to 7 days of starting 15 to 20 mg/day prednisone, the diagnosis of PMR must be fundamentally questioned and alternative pathologies investigated.
• Structured Glucocorticoid Tapering Regimen:
  • *Phase 1 (Induction):* Maintain the initial effective dose (12.5 to 25 mg/day) for 3 to 4 weeks until complete clinical remission is attained and acute-phase reactants (ESR and CRP) normalize.
  • *Phase 2 (Consolidation):* Taper the daily dose to 10 mg/day over 4 to 8 weeks (e.g., reducing by 2.5 mg every 2 to 4 weeks).
  • *Phase 3 (Maintenance & Cessation):* Once at 10 mg/day, taper slowly by 1 mg every 4 weeks (or 1.25 mg every 4 weeks using alternate-day dosing) provided clinical remission is maintained. Tapering faster than 1 mg per month below 10 mg/day is the leading trigger of disease relapse.
  • *Total Duration:* The anticipated duration of glucocorticoid therapy ranges from 12 to 24 months. Attempting complete withdrawal within less than 12 months results in relapse rates exceeding 60% to 70%.
• Management of Relapse: If clinical symptoms and inflammatory markers recur during tapering, the prednisone dose should be increased to the previously effective dose before the taper step, maintained for 2 to 4 weeks, and then tapered again at a more conservative rate.
• Steroid-Sparing Disease-Modifying Antirheumatic Drugs (DMARDs):
  • Methotrexate: Oral or subcutaneous methotrexate (10 to 15 mg once weekly with folic acid 5 mg/week) is conditionally recommended by 2015 EULAR/ACR guidelines for patients at high risk of relapse, patients experiencing recurrent flares during tapering, or those with severe comorbidities where glucocorticoid exposure must be strictly curtailed (brittle diabetes, severe osteoporosis, poorly controlled hypertension).
  • Interleukin-6 Receptor Antagonists (Sarilumab): In 2023, the fully human anti-IL-6 receptor monoclonal antibody sarilumab (200 mg subcutaneously every 2 weeks) received FDA approval for the treatment of adult patients with PMR who have an inadequate response to corticosteroids or cannot tolerate corticosteroid taper. Approval was based on the landmark phase 3 SAPHYR trial, which demonstrated a 28% sustained remission rate at 52 weeks in the sarilumab group compared to 10% in the placebo group, with a massive reduction in cumulative steroid exposure. Tocilizumab has similarly shown robust steroid-sparing efficacy in randomized phase 2/3 trials.
  • Anti-TNF Therapy (Contraindicated): Tumor necrosis factor inhibitors (infliximab, etanercept, adalimumab) are completely ineffective in PMR. Multiple randomized trials showed no therapeutic benefit and excess adverse effects; anti-TNF agents are strongly recommended against.
• Prophylaxis Against Glucocorticoid-Induced Toxicity:
  • *Bone Protection:* Obtain baseline dual-energy X-ray absorptiometry (DEXA) scan. Prescribe elemental calcium (1000 to 1200 mg/day) and vitamin D (800 to 2000 IU/day). Initiate antiresorptive therapy (oral alendronate 70 mg weekly, risedronate 35 mg weekly, or IV zoledronic acid 5 mg annually) in patients with a history of fragility fracture, T-score < -1.5, or FRAX 10-year major osteoporotic risk >= 20% receiving >= 7.5 mg/day prednisone for > 3 months.
  • *Metabolic and Gastrointestinal Monitoring:* Monitor fasting plasma glucose, HbA1c, blood pressure, and weight. Initiate proton pump inhibitor (PPI) therapy in patients with prior peptic ulcer disease or concurrent anticoagulant/antiplatelet use. Baseline and periodic ophthalmological screening for cataracts and glaucoma.

Operative

Operative intervention has zero therapeutic role in the management of primary polymyalgia rheumatica. Surgical considerations are strictly confined to diagnostic pathology and the prevention of orthopaedic misadventure:

• Absolute Surgical Contraindication for Primary PMR: PMR is a medically managed systemic inflammatory condition. There is no indication for arthroscopic subacromial decompression, acromioplasty, rotator cuff debridement, or joint arthroplasty for isolated PMR symptoms. Surgical intervention does not alter the underlying cytokine-driven disease process and exposes elderly patients to operative risks and severe postoperative antalgic stiffness.
• Diagnostic Temporal Artery Biopsy (TAB) for Suspected GCA:
  • *Indications:* Emergent evaluation when a PMR patient exhibits cranial manifestations (temporal headache, scalp tenderness, jaw claudication, visual disturbance) or unexplained constitutional deterioration.
  • *Technical Principles:* Performed under local anesthesia. The surgeon must harvest a specimen length of at least 1.5 to 2.5 cm because GCA lesions are segmental (“skip lesions”). The incision must be placed within or posterior to the temporal hairline to prevent injury to the frontal branch of the facial nerve.
  • *Zero Glucocorticoid Delay:* Administration of high-dose systemic glucocorticoids (prednisone 40 to 60 mg/day orally or IV methylprednisolone 1000 mg/day for visual symptoms) must never be delayed while awaiting biopsy, as typical histopathological hallmarks persist for up to 2 to 4 weeks following corticosteroid initiation.
• Preventing the “Rotator Cuff Trap” and Orthopaedic Misadventure: An elderly patient presenting with severe bilateral shoulder pain and MRI demonstrating rotator cuff fraying or partial tears alongside subacromial fluid is frequently misdiagnosed with bilateral degenerative rotator cuff impingement. If scheduled for arthroscopic debridement or cuff repair without recognizing the systemic polymyalgic syndrome, the patient experiences poor functional recovery, persistent postoperative pain, and delayed medical care. Orthopaedic surgeons must screen for morning stiffness and inflammatory markers in all elderly patients presenting with bilateral shoulder girdle symptoms.

Indications & Contraindications

Explicit clinical and laboratory thresholds governing management decisions:

• Indications for Low-Dose Corticosteroid Induction (Prednisone 12.5 to 25 mg/day): Age >= 50 years, bilateral shoulder and/or pelvic girdle pain with morning stiffness > 45 minutes, elevated ESR (> 40 mm/hr) and/or CRP (> 10 mg/L), normal muscle enzymes (CK), and exclusion of active infectious or neoplastic processes.
• Indications for High-Dose Corticosteroid Escalation (Prednisone 40 to 60 mg/day): Presence of any cranial GCA features: new localized headache, scalp tenderness, jaw claudication, visual loss, or amaurosis fugax. Immediate intravenous pulse methylprednisolone (500 to 1000 mg/day for 3 days) is indicated for acute visual symptoms.
• Indications for Adjuvant Steroid-Sparing Biologic/DMARD Therapy: Two or more disease relapses during corticosteroid taper, inability to taper prednisone below 10 mg/day, severe glucocorticoid adverse effects (osteoporotic fracture, uncontrolled hyperglycemia), or high baseline fracture/metabolic risk.
• Contraindications:
  • Elective orthopaedic arthroscopic or arthroplasty procedures during active, untreated PMR.
  • High-dose corticosteroids (> 30 mg/day) in isolated PMR without clinical or laboratory suspicion of GCA.
  • Anti-TNF biological agents (infliximab, etanercept, adalimumab) in PMR.
  • Rapid corticosteroid tapering (> 1 mg/month reduction when below 10 mg/day).

9. Outcome

The prognosis of polymyalgia rheumatica under structured medical management is highly favorable regarding functional restoration, but long-term outcomes are influenced by relapse frequency and the cumulative burden of glucocorticoid-related morbidity.

Remission Benchmarks and Relapse Trajectory

Clinical remission is defined by international consensus as the complete resolution of musculoskeletal signs and symptoms, morning stiffness duration <= 15 minutes, and normalization of ESR and CRP, achieved on a daily prednisone dose <= 5 mg or complete corticosteroid cessation. Key outcome metrics include:

• Initial Remission Rate: Over 95% of patients achieve initial complete clinical remission within 2 to 4 weeks of starting 15 to 20 mg/day prednisone.
• Relapse Incidence: Approximately 45% to 55% of patients experience at least one disease flare during the course of corticosteroid tapering. Relapses cluster heavily during the first year of therapy and when the daily prednisone dose is tapered below 10 mg/day.
• Duration of Treatment: The median duration of corticosteroid therapy required to achieve permanent, treatment-free remission is 18 to 24 months. Approximately 30% to 40% of patients successfully discontinue corticosteroids at 12 to 18 months, whereas 25% require prolonged low-dose maintenance therapy (2.5 to 5 mg/day) beyond 3 to 4 years.

Polymyalgia Rheumatica Activity Score (PMR-AS)

The Polymyalgia Rheumatica Activity Score (PMR-AS) is the validated disease-specific assessment tool recommended by EULAR/ACR for clinical practice and clinical trials. It quantitatively aggregates subjective, objective, and laboratory parameters:

PMR-AS Formula:
PMR-AS = CRP (mg/dL) + VAS Pain (0–10) + VAS Patient Global (0–10) + VAS Physician Global (0–10) + [Morning Stiffness (minutes) × 0.1]

(Note: When utilizing ESR instead of CRP, the formula substitutes [ESR (mm/hr) / 40] for CRP).

• PMR-AS < 1.5: Complete Clinical Remission.
• PMR-AS 1.5 to 7.0: Low Disease Activity.
• PMR-AS 7.1 to 17.0: Medium Disease Activity.
• PMR-AS > 17.0: High Disease Activity.

Functional Recovery and Patient-Reported Outcome Measures

Patients demonstrate rapid, dramatic improvements in validated Patient-Reported Outcome Measures (PROMs). Health Assessment Questionnaire Disability Index (HAQ-DI) scores improve by > 70% within 4 weeks of treatment initiation. Shoulder-specific and general functional instruments (ASES score, QuickDASH, SF-36 Physical Component Summary) normalize rapidly once periarticular bursitis subsides.

Long-term mortality in patients with uncomplicated PMR is identical to age-matched controls in the general population. However, overall quality of life is heavily dictated by the avoidance of cumulative corticosteroid-induced complications, reinforcing the necessity of adopting modern treat-to-target protocols targeting steroid minimization (<= 5 mg/day by 12 months).

10. Complications

Complications in polymyalgia rheumatica bifurcate into primary disease-related complications (chiefly vascular ischemia from concomitant arteritis) and treatment-related complications arising from cumulative systemic glucocorticoid exposure.

11. Pearls and Pitfalls

Mastery of polymyalgia rheumatica requires navigating nuanced diagnostic presentations and avoiding common clinical traps:

Critical Clinical Pearls

• The 72-Hour Glucocorticoid Test: An immediate, dramatic clinical response (> 70% to 80% improvement in pain and morning stiffness) within 48 to 72 hours of initiating 15 to 20 mg/day prednisone is an indispensable diagnostic validation. Failure to experience life-altering symptomatic relief within 5 to 7 days is a major red flag indicating that the diagnosis of PMR is almost certainly incorrect; halt the taper and rigorously investigate alternative diagnoses.
• The Passive-Active Range of Motion Discrepancy: When examining the painful PMR shoulder, active forward elevation is severely restricted by muscle guarding, often stopping at 60 to 90 degrees. However, when the examiner gently supports the arm and takes over the weight, passive forward flexion and external rotation can be executed smoothly through a full or near-full arc. This immediate clinical test excludes adhesive capsulitis and advanced glenohumeral osteoarthritis within seconds in the clinic.
• Dual Inflammatory Marker Surveillance: While ESR is the classic marker, 10% to 15% of patients with genuine PMR present with a normal or borderline ESR (< 30 mm/hr). In contrast, C-reactive protein (CRP) is significantly more sensitive (approaching 98%) and possesses superior kinetic response. Always order both ESR and high-sensitivity CRP at baseline and during follow-up monitoring.
• Micro-Tapering Below 10 mg/Day: The “danger zone” for PMR relapse is between 10 mg and 5 mg of prednisone. Once the daily dose reaches 10 mg, decelerate the taper to reductions of no more than 1 mg every 4 weeks (or 1.25 mg every 4 weeks using alternate-day tablets). Patience during this critical threshold prevents recurring flares that force clinicians to restart high doses.
• Screening for GCA at Every Single Visit: Never assume a PMR patient is free from giant cell arteritis simply because they were stable at initial presentation. Concomitant GCA can emerge months into glucocorticoid tapering. Specifically interrogate for new temporal headache, scalp tenderness when brushing hair, jaw claudication when chewing, and transient visual blurring at every follow-up appointment.

Diagnostic and Technical Pitfalls

• The “Rotator Cuff Trap”: Performing shoulder arthroscopy, subacromial decompression, or rotator cuff debridement in an older adult who actually has undiagnosed PMR. Because degenerative partial-thickness supraspinatus tears and subacromial fluid are ubiquitous on MRI in adults over 70, clinicians mistakenly attribute systemic inflammatory pain to structural cuff pathology. Surgery leads to severe postoperative stiffness, functional worsening, and delayed systemic therapy.
• Confusing PMR with Late-Onset Rheumatoid Arthritis (LORA): LORA frequently presents in older adults with acute, symmetric shoulder and hip girdle aching accompanied by profound morning stiffness, perfectly masquerading as PMR. Always check rheumatoid factor (RF) and anti-cyclic citrullinated peptide (anti-CCP). If serology is positive, or if persistent peripheral small-joint synovitis (MCP, PIP, MTP) is detected, manage the condition as rheumatoid arthritis.
• Steroid Megadosing for Isolated PMR: Initiating prednisone at 40 to 60 mg/day for isolated PMR in the absence of cranial GCA symptoms. High doses provide no superior therapeutic advantage over 15 to 20 mg/day, but exponentially increase the incidence of glucocorticoid-induced diabetes, avascular necrosis, vertebral collapse, and severe psychiatric disturbances.
• Missing Occult Malignancy and Paraneoplastic Syndromes: Multiple myeloma, monoclonal gammopathy of undetermined significance (MGUS), renal cell carcinoma, and lymphoma can present with polymyalgic proximal girdle symptoms and elevated ESR/CRP. In patients who fail to achieve complete remission within 4 weeks of steroid therapy, obtain serum protein electrophoresis (SPEP), serum free light chains, and chest/abdomen/pelvis CT.
• Abrupt Glucocorticoid Withdrawal Triggering Adrenal Crisis: Stopping or aggressively cutting corticosteroids due to fear of steroid side effects. Long-term steroid therapy suppresses the hypothalamic-pituitary-adrenal (HPA) axis; rapid cessation triggers catastrophic disease rebound and life-threatening acute adrenal insufficiency (severe hypotension, vomiting, hyponatremia, hypoglycemia, vascular collapse).

12. Controversy

Several major controversies and evolving management paradigms actively shape contemporary clinical discourse in polymyalgia rheumatica:

• Optimal Glucocorticoid Tapering Velocity: Substantial debate persists regarding fixed-schedule tapering regimens versus biomarker-guided individualized tapering. Proponents of rapid tapers (aiming for discontinuation by 6 to 9 months) argue that curtailing cumulative steroid exposure is paramount to avoid osteoporosis and diabetes. Conversely, advocates of prolonged, conservative micro-tapers (extending 18 to 24 months) point to prospective trial data demonstrating that rapid tapers trigger relapse rates exceeding 65%, paradoxically resulting in higher cumulative steroid exposure when patients require repeated rescue courses. Modern consensus leans toward conservative micro-tapering below 10 mg/day targeting complete cessation by 18 to 24 months.
• First-Line Biologic Therapy (IL-6 Inhibition) versus Glucocorticoid Monotherapy: With the FDA approval of sarilumab for steroid-resistant or relapsing PMR following the SAPHYR trial, debate centers on whether targeted IL-6 receptor antagonists should be introduced first-line in patients at high baseline risk of glucocorticoid toxicity. Proponents emphasize that upfront IL-6 inhibition could spare elderly patients with severe pre-existing osteoporosis, brittle diabetes, or cardiovascular disease from the catastrophic adverse effects of systemic steroids. Skeptics argue that low-dose oral prednisone costs pennies per day, achieves rapid remission in over 90% of patients, and that routine early biologic therapy is cost-prohibitive while introducing risks of severe infection, bowel perforation, and neutropenia. Current international guidelines restrict biologic initiation to relapsing or steroid-intolerant cohorts.
• Subclinical Large-Vessel Vasculitis on PET-CT: Advanced imaging studies utilizing 18F-FDG PET/CT reveal that 15% to 30% of patients presenting with pure, classic PMR without cranial symptoms exhibit high-grade hypermetabolic uptake along the thoracic aorta, subclavian, and axillary arteries. The management implication of this finding remains fiercely contested. One school of thought contends that subclinical aortitis demands immediate escalation to high-dose immunosuppression (prednisone 40 to 60 mg/day plus DMARDs) to prevent late aortic wall remodeling and thoracic aortic aneurysm formation. The opposing perspective asserts that routine PET-CT screening is unwarranted, that low-dose prednisone adequately suppresses vascular wall inflammation in most patients, and that overtreatment with toxic steroid doses carries greater mortality than the rare incidence of late aneurysm rupture.
• Mandatory Point-of-Care Ultrasound versus Pure Clinical Diagnosis: While the 2012 EULAR/ACR criteria incorporate bilateral shoulder/hip ultrasound to boost diagnostic specificity (from 78% to 82%), practical adoption remains inconsistent. Enthusiasts advocate that bedside MSUS should be mandatory before starting steroids to confirm bilateral SASD bursitis and rule out structural mimics (complete rotator cuff tears, glenohumeral chondrocalcinosis). Critics counter that musculoskeletal ultrasound is highly operator-dependent, unavailable in many primary care and community settings, and that requiring imaging delays immediate low-dose glucocorticoid initiation in excruciatingly painful, classic presentations.

13. Evidence-Based Synthesis

Modern clinical decision-making is grounded in high-quality randomized controlled trials and prospective registry analyses, corroborated by seminal biomechanical and anatomical descriptions.

14. References

• Dasgupta B, Cimmino MA, Maradit-Kremers H et al. 2012 provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. Ann Rheum Dis. 2012. doi:10.1136/annrheumdis-2011-200329 [Level II (Diagnostic): Prospective Multicenter Validation Study]
• Dejaco C, Singh YP, Perel P et al. 2015 Recommendations for the Management of Polymyalgia Rheumatica: A European League Against Rheumatism/American College of Rheumatology Collaborative Initiative. Arthritis & Rheumatology. 2015. doi:10.1002/art.39333 [Level I (Therapeutic): Clinical Practice Guideline & Systematic Review]
• Buttgereit F, Dejaco C, Matteson EL et al. Polymyalgia Rheumatica and Giant Cell Arteritis: A Systematic Review. JAMA. 2016. doi:10.1001/jama.2016.5444 [Level I (Therapeutic): Systematic Review / Meta-Analysis]
• Dejaco C, Kerschbaumer A, Aletaha D et al. Treat-to-target recommendations in giant cell arteritis and polymyalgia rheumatica. Ann Rheum Dis. 2024. doi:10.1136/ard-2022-223429 [Level I (Therapeutic): Systematic Review & International Consensus]
• Hahn J, Cook NR, Alexander EK et al. Vitamin D and marine omega 3 fatty acid supplementation and incident autoimmune disease: VITAL randomized controlled trial. BMJ. 2022. doi:10.1136/bmj-2021-066452 [Level I (Preventive): Randomized Controlled Trial]

15. Master Class Pro-Tip

When evaluating an older adult presenting with sudden, debilitating bilateral shoulder girdle pain, resist the reflex to attribute symptoms solely to degenerative rotator cuff tears or subacromial impingement seen on advanced imaging. Always assess passive range of motion, palpatory girdle tenderness, and acute phase reactants (both ESR and high-sensitivity CRP) before recommending orthopaedic intervention. Initiating a diagnostic therapeutic trial of low-dose prednisone (15 to 20 mg once daily in the morning) yields dramatic, life-altering symptomatic relief (> 70% reduction in stiffness and pain) within 48 to 72 hours in polymyalgia rheumatica. A failure to demonstrate profound clinical improvement within 5 to 7 days is an absolute mandate to halt the taper, abandon the diagnosis, and rigorously investigate alternative diagnoses such as late-onset rheumatoid arthritis, calcium pyrophosphate deposition disease, occult spondylodiscitis, or paraneoplastic syndromes. Above all, screen diligently for cranial features of giant cell arteritis at every visit, as prompt high-dose glucocorticoid escalation is the sole barrier against irreversible ischemic optic neuropathy.

Master Class Clinical Pearl: Polymyalgia Rheumatica Diagnostic & Management Benchmarks